Workers’ Comp Executive recently studied the issue of whether or not the Division of Workers’ Compensation is biased against RPNA client Electronic Waveform Labs, maker of the H-Wave electronic stimulation device.
According to the article, the dispute stems from the proposed update of the Medical Treatment Utilization Schedule’s chronic pain guidelines and the development of a new section on opioids, where electroanalgesia, or H-wave therapy, is eliminated. The proposed regulations as amended either preclude the use of the device to treat injured workers in California or impose such a burden as to make it impractical for a doctor to recommend its usage.
H-Wave’s attorney Nick Roxborough suggested there was some kind of personal animus on the part of regulators that caused them to eliminate H-wave therapy and said he has obtained the “smoking gun” e-mail to show that bias is swaying the states’ rule making.
According to the article, the dispute stems from the proposed update of the Medical Treatment Utilization Schedule’s chronic pain guidelines and the development of a new section on opioids, where electroanalgesia, or H-wave therapy, is eliminated. The proposed regulations as amended either preclude the use of the device to treat injured workers in California or impose such a burden as to make it impractical for a doctor to recommend its usage.
H-Wave’s attorney Nick Roxborough suggested there was some kind of personal animus on the part of regulators that caused them to eliminate H-wave therapy and said he has obtained the “smoking gun” e-mail to show that bias is swaying the states’ rule making.
“There was no intervening study that triggered this. What triggered this was the June 4 e-mail,” he said referring to a June 2014 e-mail from DWC Medical Director Rupali Das to the chair of the American College of Occupational and Environmental Medicine (ACOEM) Occupational Medicine Practice Guidelines.
To read the story, visit Workers’ Comp Executive here. (subscription required).
